Plataformas Broadcast
Soluções de Dados e Conteúdos
Broadcast OTC
Plataforma para negociação de ativos
Broadcast Datafeed
APIs para integração de conteúdos e dados
Broadcast Ticker
Cotações e headlines de notícias
Broadcast Widgets
Componentes para conteúdos e funcionalidades
Broadcast Wallboard
Conteúdos e dados para displays e telas
Broadcast Curadoria
Curadoria de conteúdos noticiosos
Selecione abaixo qual plataforma deseja acessar.
23 de junho de 2026
China continues to be a major player in the pharma industry. Its role has evolved to become a strategic imperative for the entire ecosystem, from large pharmas through to venture capitalists and start-ups. Chinese assets are forecast to make up more than two-thirds of total deal value in 2026, up from a half in 2025 and less than 5% five years ago. These deals are becoming less transactional and increasingly collaborative, pointing towards Chinas longer-term ambitions.
The 2026 World Preview Reports findings give us confidence that, despite regulatory uncertainties and an increase in competition across the globe, the pharmaceutical market is fundamentally strong, said Daniel Chancellor, Vice President of Thought Leadership at Norstella, Evaluates parent company. However, as patents expire and global competition intensifies, its becoming increasingly clear that the industry is at the edge of shift. How pharma prepares for this transition will define whether its current momentum can be sustained throughout the next decade.
In addition to answering these urgent questions, the World Preview Report also outlines:
Additional analysis is included in the full report, which is available here, and a webinar featuring discussion and insight from the report is available on demand here.
About Evaluate Ltd
Since 1996, Evaluate has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary & industry data into their workflows, tools and processes so they can work more effectively and efficiently. For more information about Evaluate, visit www.evaluate.com and follow us on LinkedIn and X.
About Norstella
Norstella is a global life sciences company whose brands Citeline, Evaluate, MMIT, Panalgo, Skipta, and the Dedham Group provide cutting-edge technology, unparalleled data, and expert insights and consultancy across the drug development lifecycle. Norstellas AI engine supports decision-making across forecasting, clinical trial design & regulatory strategy, market access, and patient activation. With the patient at the center, Norstella smooths the path to life-saving therapies for patients and providers. For more information, visit Norstella and follow on LinkedIn.
For media inquiries, please contact:
norstella@diffusionpr.com
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Veja também
